Recce’s Phase 2 trial for skin infections hits midway recruitment milestone
Recce sees progression of Phase 2 study assessing efficacy of RECCE® 327 (R327G) topical gel against acute bacterial skin and...
Phase
Phase II PREDICT-ILD Imaging Study Commences in Interstitial Lung Disease
LONDON, Sept. 10, 2024 /PRNewswire/ -- Serac Healthcare Limited ("Serac Healthcare" or "the Company"), a clinical radiopharmaceutical company developing innovative...
